Stabilizing technical baseline with base-building active, despite temporary fundamental deterioration. Valuations remain conservative and supported by current metrics.
SENTINEL REVIEW
Dhampur Bio Organics (DBOL)β’Updated yesterday
π¨ Structural Deterioration Signature: In FY2026, Dhampur Bio Organics demonstrates an underlying operational disconnect, where reported revenue growth of 17.4% to βΉ3165.2 Cr and a reported net profit of βΉ25.2 Cr (up 71.4% YoY) mask severe structural margin erosion. Operating profitability has entered negative territory, evidenced by EBIT margins compressing from 0.1% to -5.6% YoY under persistent cost-push pressures and negative operating leverage. This operational strain is transmitted through working-capital friction: inventory accumulation reached βΉ1013.2 Cr alongside an accelerating receivables-revenue divergence, perpetuating persistent interest coverage deficits. Coinciding with total debt of βΉ1054.2 Cr (D/E of 1.03), heightened governance strain from multiple director resignations firmly places the company within Flagiumβs heightened surveillance range.
- βRisk score deteriorated (QoQ change: +30 pts)
- βProfitability margins remain stressed
- βWorking Capital Expansion resolved this quarter (8 pts)
- βNew risk trigger: Industrial Margin Stress (+14.8 pts)
- βGrowth expectations are conservative
- βMarket structure is strong
- βInstitutional flow regime is Neutral (0.20Ο)
- βShare price is up +0.0% this quarter (from βΉ126.1 on 30 Sept to βΉ126.14)
- π΄Investigate Governance Integrity Shock and balance sheet impact
- π’Working Capital Expansion resolved in latest filing; verify sustainability in next filing
- π’Maintain routine quarterly surveillance; no governance escalation required
- 18.2 ptsBalance Sheet Stress
- 13.0 ptsGovernance
- 10.0 ptsGrowth Sustainability
- 8.6 ptsEarnings Quality
Divergence Radar
Structural Matrix
Risk vs Price TimelineVisualizing the historical relationship between the structural risk score and stock price movement over time.
| Duration | Perf. | Sector Avg | Divergence |
|---|---|---|---|
| 1 Week | -6.6% | -1.46% | -5.14% |
| 1 Month | +2.74% | -6.69% | +9.44% |
| 6 Months | +0.85% | +6.82% | -5.98% |
| 1 Year | +57.69% | +8.93% | +48.77% |
| 2 Year | +1.41% | +47.64% | -46.24% |
| 3 Year | -17.44% | +125.5% | -142.93% |
Business Analysis Methodology
Business analysis focuses on structural risk inside the company. Flagium monitors earnings quality, balance sheet strength, liquidity, governance, competitive position, and growth sustainability to identify areas where risk may be increasing or decreasing before it becomes obvious in reported results.
Some early signs of pressure are visible. Weakness is detected in balance sheet stress. This suggests a building risk profile. Risk is increasing at a faster pace.
Risk Score Composition
Investment Risk Thesis
Current risk score has risen from 4 β 50 over 14 quarters.
- Operating profit margins
- Interest coverage ratio
- Inventory turnover
Risk Drivers (Active Warnings)
Primary Driver & Insights
Governance Integrity Shock is currently the primary contributor to forensic pressure. Ongoing monitoring of cash generation and balance sheet quality is warranted in upcoming quarters.
Active Risk Objects (11)Free Preview (2 of 11)
DBOL: High leadership churn detected (2 key resignations).
Severe governance failure or promoter misconduct detected. Institutional trust has collapsed.
DBOL: Trade Receivables growth outpaced Revenue by +19.8 pp (DSRI: 1.21x).
Debtor days have spiked. Customers are taking significantly longer to pay their bills.
Unlock All 11 Forensic Signals (9 Additional Warnings Gated)
Free accounts preview the top 2 highest-impact warning signals. Upgrade to Flagium Pro to inspect all 11 active forensic detectors, multi-quarter duration streaks, and financial stress metrics for Dhampur Bio Organics.
Statutory Note: Forensic signals are algorithmic quantitative observations derived from publicly filed XBRL disclosures and do not constitute allegations of legal misconduct or investment recommendations.
Unlock Interactive Signal Evidence Dossier
Access complete multi-quarter financial evidence, 5-KPI snapshot strips, diagnostic hypotheses, and 1-page forensic PDF dossiers for Dhampur Bio Organics.
Structural Risk Attribution
Deterministic quarter-on-quarter causal decomposition grounded in statutory exchange filings.
Structural History Β· Last 12 QuartersHistorical Trajectory (12Q)
Risk deteriorated materially (+30.0 pts), driven by new Industrial Margin Stress (+14.8 pts) and new Governance Integrity Shock (+13.0 pts), partially offset by Working Capital Expansion relief (-8.0 pts).
12-Quarter Structural Regimes & Landmark Inflections12Q Structural Regimes & Inflections
Risk deteriorated materially (+20.0 pts), driven by new Inventory Stress (+14.4 pts) and new Industrial Margin Stress (+9.6 pts), partially offset by Low Interest Coverage relief (-9.6 pts) and Profit Collapse relief (-2.9 pts).
Business Resilience & Benchmark Context
Overall: HEALTHYPEER COMPARISON MATRIX
Ranked surveillance & credit risk comparison against sector peers
Stable
Stable
Watch
Watch
Watch
Moderate Deterioration
* Peer comparison is based on risk signals, not valuation or returns.
Unlock 5-Year Forensic Divergence Cockpit
Access multi-year visual divergence charts (EBITDA vs CFO Cash Gap, Receivables Decoupling Spread, and Debt vs FCF Burn) for Dhampur Bio Organics.
FINANCIAL STATEMENTS
Working Capital & Forensic Monitor
Operating Cycle DisclosuresΒ·4 Fiscal Years
Working Capital Schedule (INR Cr)
| Metric / Ratio | FY2026 | FY2025 | FY2024 | FY2023 |
|---|---|---|---|---|
Trade Receivables(βΉ Cr) | 64 | 55 | 88 | 154 |
Inventories(βΉ Cr) | 1,013 | 1,094 | 1,083 | 819 |
Trade Payables(βΉ Cr) | 115 | 111 | 137 | 164 |
Net Working Capital(βΉ Cr) | 962 | 1,039 | 1,033 | 809 |
Working Capital / Sales(%) | 30.4% | 38.5% | 42.7% | 30.3% |
Cash Conversion & Operating Cycle (Days)
| Metric / Ratio | FY2026 | FY2025 | FY2024 | FY2023 |
|---|---|---|---|---|
Cash Conversion Cycle (CCC)(days) | 111d | 140d | 155d | 111d |
Debtor Days (DSO)(days) | 7d | 7d | 13d | 21d |
Inventory Days (DIO)(days) | 117d | 148d | 163d | 112d |
Creditor Days (DPO)(days) | 13d | 15d | 21d | 22d |
Forensic Accounting Monitor & Divergences
| Metric / Ratio | FY2026 | FY2025 | FY2024 | FY2023 |
|---|---|---|---|---|
Receivable Growth vs Sales (Ξ)(%) | -1.0% | -48.9% | -33.8% | β |
Inventory Growth vs Sales (Ξ)(%) | -24.8% | -10.4% | +41.4% | β |
Asset Growth vs Sales (Ξ)(%) | -20.5% | -7.8% | +20.6% | β |
Earnings-to-Cash Divergence (PAT - CFO)(βΉ Cr) | -195 | -115 | 148 | -244 |
Accrual Ratio (Accruals / Avg Assets)(%) | -8.3% | -4.9% | 6.7% | -11.7% |
Operating Cash Realisation (CFO / EBITDA)(%) | 537.6% | 741.7% | -154.7% | 263.2% |
Capitalisation Intensity (CWIP / Assets)(%) | 0.1% | 6.9% | 1.2% | 3.9% |
Industry Intelligence
FMCG Sector KPIs| Operating Driver | Quarter | Current Value | Change (QoQ) | Change (YoY) | Industry Median |
|---|---|---|---|---|---|
Gross Margin β | Q1 FY2027 | 92.9% | β | +640 bps β Operating efficiency gains | 48.5% |
Understanding FMCG KPIs
Concall & Management Takeaways
No investor earnings call transcripts transcribed for this scrip.
Earnings call intelligence is automatically populated when companies conduct quarterly earnings calls with institutional investors and publish transcripts.
Business quality remains stable.
Current forensic pressure is elevated and stable.
Key risks remain concentrated in growth sustainability and operating leverage.
The risk profile is Moderate Stress and currently deteriorating. Recent structural triggers in balance sheet stress suggest a building pressure on the underlying framework. Material forensic traces are visible in core structural metrics, indicating a progressive erosion of structural stability. Strategic vigilance is advised as structural decay is accelerating.
Market Expectation Engine
Investor Translation β’ What the market price is expecting
Expectation EngineAt the current price of βΉ126, the market expects this company to grow its net profits by -0.1% every year for the next 5 years. If you think the company will grow faster than -0.1%, current market prices reflect a discount relative to that growth assumption.
Sentinel Takeaway:The market currently expects future growth below the company's historical delivery record. Expectations appear conservative relative to the business's track record, resulting in lower expectation risk.
Using the Discounted Cash Flow (DCF) model, the market is pricing DBOL for -0.1% long-term growth versus 15.0% historical delivery. Current expectations appear achievable, and historical fundamentals provide strong support.
Business Delivery Capacity
Performance quality vs historical benchmarksHistorical business performance currently provides robust support for the market's implied growth assumptions. Improvement in revenue growth and operating efficiency would strengthen expectation support.
WHY IS EXPECTATION RISK ELEVATED?
Valuation Context
WHAT MUST HAPPEN FOR CURRENT PRICE TO BE CORRECT?
| Assumption Metric | Required (To justify current price) | Historical Delivery (Average) | Fulfillment Assessment |
|---|---|---|---|
| Revenue Growth (CAGR) | -0.1% | 15.0% | Achievable |
| Operating Margin (EBIT) | 1.7% | 1.6% | Demanding |
| Free Cash Flow Conversion | 315.8% | -26.3% | Aggressive |
*Required metrics indicate the operating efficiency and revenue expansion parameters that must be sustained long-term to justify the current stock price.
The current valuation assumes business performance below the company's historical record. Historical operating performance currently provides partial evidence that these expectations are sustainable. Continued stronger profitability would be required to justify current pricing.
Market Structure Methodology
Flagium separates Business Risk from Market Structure. Business analysis explains what is happening inside the company. Market Structure measures how investors are behaving through price trends, momentum, participation, and institutional activity. Divergences between the two often reveal important transitions before they become obvious.
The stock remains in a confirmed Stage 2 advancing phase. Although institutional participation has weakened, trend quality remains constructive while momentum is accelerating. Current price action continues to support the prevailing advance.
What Is Driving Market Structure?
Market behavior shows signs of strength while underlying fundamental risk is elevated.
Market Cycle Stage Analysis
Stan Weinstein 4-Stage CycleMomentum & Institutional Flow
Methodology & Regulatory Disclaimer
Flagium AI is an automated financial data analytics and research platform providing quantitative risk, forensic, and valuation analytics for informational and educational purposes only. Flagium AI is not registered with SEBI as a Research Analyst or Investment Adviser under SEBI regulations. These analytics do not constitute financial planning, investment advice, or recommendations to buy, sell, or hold any security.
Investments in securities market are subject to market risks. Read all the related documents carefully before investing. Please consult a SEBI-registered Investment Adviser before acting on any data presented.
π¬ Flagium Risk Brief β Track forensic risks on DBOL & 3 market anomalies weekly
See a sample issue β